These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15225662)

  • 21. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy.
    Altenburg J; de Graaff CS; van der Werf TS; Boersma WG
    Respiration; 2011; 81(1):75-87. PubMed ID: 20733282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent.
    Weber FH; Richards RD; McCallum RW
    Am J Gastroenterol; 1993 Apr; 88(4):485-90. PubMed ID: 8470625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Special drug communication teleconference. August 7, 1992.
    Ear Nose Throat J; 1992 Sep; 71(9):383-4, 387-90. PubMed ID: 1425376
    [No Abstract]   [Full Text] [Related]  

  • 24. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The safety of macrolide antibiotics: critical analysis].
    Sinopal'nikov AI; Andreeva IV; Stetsiuk OU
    Klin Med (Mosk); 2012; 90(3):23-30. PubMed ID: 22690560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of macrolide antibiotics on rat embryonic heart function in vitro.
    Nilsson MF; Webster WS
    Birth Defects Res B Dev Reprod Toxicol; 2014 Apr; 101(2):189-98. PubMed ID: 24753334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythromycin--a pro-kinetic and pro-arrhythmogenic agent.
    Kluger MT
    Anaesth Intensive Care; 1997 Jun; 25(3):318-9. PubMed ID: 9209631
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of prokinetic drugs for treatment of postoperative ileus in the horse.
    Dart AJ; Hodgson DR
    Aust Vet J; 1998 Jan; 76(1):25-31. PubMed ID: 9578763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypokalemia: a potent risk for QTc prolongation in clarithromycin treated rats.
    Karmakar S; Padman A; Swamy Mane N; Sen T
    Eur J Pharmacol; 2013 Jun; 709(1-3):80-4. PubMed ID: 23567068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-9 Alkenylidine bridged macrolides: WO2008061189. Enanta Pharmaceuticals, Inc.
    Poce G; Cesare Porretta G; Biava M
    Expert Opin Ther Pat; 2009 Jun; 19(6):901-6. PubMed ID: 19473109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The design of novel classes of macrolides for neutrophil-dominated inflammatory diseases.
    Eraković Haber V; Bosnar M; Kragol G
    Future Med Chem; 2014 Apr; 6(6):657-74. PubMed ID: 24895894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empirical-Bayes adjustment improved conventional estimates in postmarketing drug-safety studies.
    Bagnardi V; Botteri E; Corrao G
    J Clin Epidemiol; 2006 Nov; 59(11):1162-8. PubMed ID: 17027426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.
    Bosnar M; Kragol G; Koštrun S; Vujasinović I; Bošnjak B; Bencetić Mihaljević V; Marušić Ištuk Z; Kapić S; Hrvačić B; Brajša K; Tavčar B; Jelić D; Glojnarić I; Verbanac D; Culić O; Padovan J; Alihodžić S; Eraković Haber V; Spaventi R
    J Med Chem; 2012 Jul; 55(13):6111-23. PubMed ID: 22697905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
    Calderone V; Cavero I
    Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Macrolides].
    Aubert G
    Rev Pneumol Clin; 1988; 44(3):122-7. PubMed ID: 3057561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disopyramide: interactions with marcolide antibiotics.
    Prescrire Int; 2001 Oct; 10(55):151. PubMed ID: 11824433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment: the new macrolide antibiotics and terfenadine.
    Cortese LM; Bjornson DC
    Ann Pharmacother; 1992; 26(7-8):1019. PubMed ID: 1504390
    [No Abstract]   [Full Text] [Related]  

  • 39. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials.
    Corrao G; Botteri E; Bagnardi V; Zambon A; Carobbio A; Falcone C; Leoni O
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):31-40. PubMed ID: 15390219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antibacterial activity of novel bifunctional macrolides.
    Akritopoulou-Zanze I; Phelan KM; Marron TG; Yong H; Ma Z; Stone GG; Daly MM; Hensey DM; Nilius AM; Djuric SW
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3809-13. PubMed ID: 15203167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.